Abstract library

63 results for "heart valves".
#1272 Telotristat Etiprate Appears to Halt Carcinoid Heart Disease
Introduction: Carcinoid Heart Disease (CHD) is a serious complication of the Carcinoid Syndrome (in as many as 50% of patients during the course of their disease). 46% of cases operated with bioprosthetic valves develop recurrent carcinoid valvulopathy on the newly implanted tissue valves. Until now, only mechanical prosthetic valves avoid recurrent fibrosis.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Others
Presenting Author: MD, FACC, FCCP Jerome Zacks
#2164 A Case of Carcinoid Induced Heart Disease
Introduction: Carcinoid Heart disease is a common disease with neuroendocrine malignancies that invade the liver due to the paraneoplastic effects of vasoactive substances such as 5-hydroxytryptamine, histamine and tachykinins released by malignant cells rather than any direct metastatic involvement of the heart.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: doctor Suhel Ashraff
#230 Long-term Follow-up of Tissue Valve Prostheses in Carcinoid Heart Disease
Introduction: Development of carcinoid heart disease (CHD) increases morbidity and mortality. Cardiac valve replacement surgery improves functional class, but tissue prosthesis degeneration can occur early in CHD.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Daniel S Knight
#1138 Staged Percutaneous Treatment of Severe Carcinoid Heart Disease by Transfemoral Pulmonary Valve Replacement and Novel Vena Cava Valve Implantation
Introduction: Carcinoid heart disease with severe valve destruction represents the major cause of high morbidity and mortality in patients with carcinoid syndrome.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: Dr René Pschowski
Authors: Pschowski R, Laule M, Baur A, Pape U F, ...
#1997 Carcinoid Heart Disease - Diagnostic Usefulness of Cardiac Computed Tomography – A Pilot Study
Introduction: Carcinoid heart disease (CHD) is a rare entity which occurs from 20 to 40% patients with carcinoid syndrome.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Ilona Michałowska
#104 Myocardial motion abnormalities in patients with carcinoid disease without overt carcinoid heart disease
Introduction: Cardiac abnormalities occur in 15-70% of patients with carcinoid disease, typified by fibrosis of the right-sided valves. Myocardial motion abnormalities in subjects without overt carcinoid heart disease have not been previously described. Tissue Doppler Imaging (TDI) allows quantative analysis of myocardial motion. We used this technique to investigate whether myocardial motion is reduced, suggesting fibrosis, in patients with carcinoid disease.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Christopher Wong
#2833 Surgical Correction of Carcinoid Heart Disease Improves Liver Function and 5-Hydroxyindoleacetic Acid Levels
Introduction: Neuroendocrine tumours of the gastrointestinal tract cause carcinoid syndrome and carcinoid heart disease. These tumours secrete serotonin, which can bind to heart valves and cause fibrosis and valve incompetence. Most cases involve the tricuspid valve +/- pulmonary valve. Medical management comprises diuretics for fluid overload and somatostatin analogues to reduce circulating serotonin. Definitive treatment is heart-valve replacement surgery which improves exercise tolerance but has high perioperative mortality. We have previously reported that valve-replacement surgery can reduce 5-hydroxyindoleacetic acid (5-HIAA) levels, reflecting a decline in hormone activity.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Tahir Shah
#105 A pilot study using biochemical markers to predict acrcinoid heart disease in patients with carcinoid disease
Introduction: Carcinoid heart disease (CHD) affects up to 15-70% of patients with carcinoid disease. Recent ENETS guidelines recommend regular echocardiographic assessment to screen for CHD. Chromogranin A (CgA) is a peptide widely used to monitor carcinoid disease progression. Neurokinin A is a tachykinin which may be a more sensitive measure of carcinoid disease progression and prognosis. N-terminal pro Brain Naturetic Peptide is used as a screening tool for heart failure and recent results suggest utility in the diagnosis of CHD.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Christopher Wong
#1762 Prevalence of Carcinoid Heart Disease in Patients with Disseminated Small Intestinal NET
Introduction: In patients with small intestinal neuroendocrine tumours (SI-NETs), serotonin may induce fibrosis and lead to carcinoid heart disease (CHD) with right sided valvular dysfunction.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD, PhD Gitte Dam
#2260 Carcinoid Heart Failure in a Metastatic Duodenal Neuroendocrine Tumor: A Challenging Case Report.
Introduction: Carcinoid heart disease (CHD) is a potenzial fatal cardiac manifestation, characterized by fibrous endocardial thickening involving right-sided heart valves. In 70% of cases, CHD occurs in advanced small bowel NETs with carcinoid syndrome (CS). Serotonin seems to play a main role. Early recognition and surgical intervention may improve the outcome of patients.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: Dr Anna La Salvia